FDA Approves Zanidatamab for Biliary Tract Cancer

(MedPage Today) -- The FDA on Wednesday granted accelerated approval to zanidatamab (Ziihera), a bispecific antibody, for pretreated HER2-positive biliary tract cancer.
Approval stipulates use in unresectable or metastatic cases, with HER2 positivity...